Biosimilars are coming to Oncology

How will biosimilars impact the oncology market in the US? Will physician's adopt them quickly or will they need more real world evidence to trust these new entrants? What are the challenges facing oncology practices as they move toward these presumably more affordable options? I had the chance to listen to an OBR webcast last week which provided some great insight into the future of biosimilars. I found this slide from ZS to be an good summary of where we are at...